There are currently 233 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619
Recruiting
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2024
Locations: Hartford Health Care, Hartford, Connecticut
Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Register for Updates
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
NCT06087029
Recruiting
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/24/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Type B Aortic Dissection
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Lumbar Spinal Stenosis
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/23/2024
Locations: Alkermes Investigator Site, Hartford, Connecticut
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
NCT04863664
Recruiting
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/22/2024
Locations: LEADR: Hartford Hospital, Hartford, Connecticut
Conditions: Tachyarrhythmia
Register for Updates
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
NCT04165772
Recruiting
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut
Conditions: Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Register for Updates
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Recruiting
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/22/2024
Locations: Connecticut Clinical Research Institute, Hartford, Connecticut
Conditions: Colorectal Cancer
Register for Updates
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
04/19/2024
Locations: Connecticut Gastroenterology, Hartford, Connecticut +1 locations
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
04/19/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398
Recruiting
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors wil... Read More
Gender:
All
Ages:
25 years and below
Trial Updated:
04/18/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Register for Updates
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585
Recruiting
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
04/18/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Register for Updates
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318
Recruiting
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
04/18/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Register for Updates